|
Neonatal Intensive Care Drug Manual
|
| bet | 402/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Nystatin
Revision Date : 24-12-2020
|
Approved : TC, KOH
|
Alert
|
The Antimicrobial Stewardship Team listed this drug under the following category: Unrestricted.
Nystatin is not suitable for the treatment of invasive fungal disease.
|
Indication
|
1) Prophylaxis in infants at high risk for invasive fungal infections. Criteria for prophylaxis should be determined by local policy. Indications may include: Infants ≤ 28 weeks gestation at birth or < 1000 g birth weight or larger infants with risk, factors including use of broad spectrum antibiotics, having a central venous access device, (PICC/UVC/CVC), receiving parenteral nutrition or inhaled steroids.
2) Treatment of mucocutaneous candidiasis.
|
Action
|
Fungicidal agent which works by combining with the sterol elements of fungal cell membranes, causing cell death by producing increased cell wall permeability.
|
|
|
| |
